Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 8, 2026 · Other material event · Investor press release · Financial statements
Tango Therapeutics, Inc.
40
Other material event
Jun 8, 2026
| Form type | Current report (Form 8-K) |
| Event summary | Other material event · Investor press release · Financial statements |
| Primary topic | Other material event |
| About this form | Public companies file this within four business days when something important happens that investors should know about, before the next quarterly report. |
| Why this was filed | Tango Therapeutics, Inc. filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. 1 Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability of clinical… |
| Labor angle | Watch for Item 2.05 (restructuring or severance), Item 5.02 (leadership changes), and Item 1.01 (major contracts that can precede workforce shifts). |
| Period of report | Jun 8, 2026 |
| Accession number | 0001193125-26-260679 |
| Reported items | Regulation FD disclosure (investor press release or presentation), Other events the company considers material, Financial statements and exhibits See Analysis tab for workforce implications |
